AI-generated · cited to primary sources · not investment advice · How we research
Aurobindo Pharma
Our verdict on Aurobindo Pharma isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company confirmed that Dazublys (trastuzumab biosimilar) received marketing authorization from the European Commission. (3 met, 1 revised, 1 in progress across 5 tracked commitments)
“BP16 (Prolia biosimilar) met Phase 3 endpoints in a clinical study across 5 European countries, ready for regulatory submission in the next Quarter.”
The company generated $118 million in free cash flows during Q3FY26, exceeding the $100 million quarterly target. (2 exceeded, 2 missed, 1 met across 5 tracked commitments)
“Last but not least, we are confident of achieving our internal margin target of 20%-21% for FY26, as communicated earlier.”
The facility has reached an annualized production level of 9,000 to 10,000 metric tonnes as of January 2026, indicating significant progress toward the 15,000 MT target. (1 in progress across 1 tracked commitment)
“which will support the further ramp-up in achieving 100% capacity utilization, taking the production to 15,000 MT in a very short term.”
The European business showed strong momentum with 27.4% YoY growth in Q3FY26, reaching ₹2,703 Cr for the quarter. (3 in progress across 3 tracked commitments)
“With consistent performance across all major markets, we are firmly on track to comfortably support the 1 billion annual revenue milestone from Europe by the end of FY26.”
Total Capex for the TheraNym (CDMO) business for two products is projected at USD 120 to 130 million. — target: USD 120 to 130 million (+1 more commitment)
“the total Capex projected, is around 120 to 130 million for both the products – (for building) the capacities for both the products together.”
See the full cited Management analysis of Aurobindo Pharma
How durable is the business?
The biosimilar moat is expanding significantly with multiple European Commission approvals and a clear timeline for US FDA submissions in FY26. (5 expanding)
“CuraTeQ Biologics – Building a global biosimilars company... A diversified portfolio of 15 products is positioned to drive and sustain CuraTeQ’s growth trajectory through 2030 and beyond”
Europe continues to be a high-growth geography, expanding its revenue share through strong performance across all key markets. (5 expanding across 1 engine)
“Europe: 2,703 [Cr]... Y-o-Y (%): 27.4%”
The ARV segment continues its strong expansion, maintaining high double-digit growth momentum. (5 expanding across 2 engines)
“Growth Markets*: 865 [Cr]... Y-o-Y (%): -0.9%... includes domestic formulation sales of Rs. 73Crs”
The US segment remains the primary engine, showing strong growth driven by new product launches and increased volume, now accounting for 48.6% of total revenue. (4 expanding)
“US ANDA Filings Snapshot as on 31st December 2025... Total ANDAs: 879... Addressable Market Size (US$ Bn): 197.2”
The API segment has shifted from contraction to growth, supported by improved capacity utilization in manufacturing facilities. (3 expanding, 1 contracting, 1 shifted across 1 engine)
“Total API: 963 [Cr]... Y-o-Y (%): -4.3%... API business posted revenues decline of 4% YoY impacted primarily by market conditions”
See the full cited Business Model analysis of Aurobindo Pharma
Where does growth come from?
The US market is showing accelerating momentum with revenue jumping 10.9% quarter-on-quarter to $470 Mn in Q4FY25, supported by 5 new product launches and 9 new filings in the quarter. (3 accelerating, 2 steady across 5 signals)
“US market: Received approval for 7 products and Launched 9 products”
The Pen-G project has hit a temporary reversal due to a fire incident and pending regulatory renewals, delaying the expected transition to profitability. (1 reversing, 2 new trend, 1 accelerating across 4 signals, 1 leading indicator)
“Based on our current production level, we expect to produce more than 10,000 metric tonnes on annualised basis over the next 12 months. It is important to note that the yield levels are steady and improving consistently over time.”
The ARV business is showing accelerating growth, with the Q4 growth rate (29%) significantly outperforming the full-year growth rate (19%). (5 accelerating across 5 signals, 3 leading indicators)
“ARV 376 307 22.4%”
Aurobindo is aggressively expanding its biologics and biosimilars capacity. New 2,500L bioreactors are being commissioned this quarter, and the TheraNym commercial scale facility (₹1,000 crore investment) is expected to be ready by June/July 2026. (2 accelerating, 1 decelerating, 2 new trend across 5 signals, 3 leading indicators)
“Our U.S. injectable sales also grew by year-on-year by 17%.”
Europe revenue is showing significant acceleration, growing from 11% YoY in the previous quarter to 27.4% YoY in Q3FY26, driven by strong performance across all key markets. (2 accelerating, 3 steady across 5 signals, 1 leading indicator)
“Europe 2,703 2,121 27.4%”
See the full cited Future Growth analysis of Aurobindo Pharma
What could break the thesis?
STABLE. The company still has a massive pipeline under review (142 ANDAs), but continues to receive approvals (5 in Q4) and file new applications (9 in Q4), maintaining high visibility for future launches. (4 stable, 1 intensifying, 1 high-severity)
“US ANDA Filings Snapshot as on 31st December 2025... Under Review 129”
The risk remains high as Eugia-3 remediation is still ongoing and the facility has not yet been cleared by the FDA. Management expects growth to be 'muted' in FY26 as a result of these disruptions. (4 stable, 1 high-severity)
“Sir, with respect to Eugia III inspection, if you could share some color in terms of the nature of observations... But ultimately, US FDA has to take a decision in terms of the warning letters. So, I cannot comment on what exactly they will do”
US revenue declined 4% YoY and 14.3% QoQ, primarily due to a significant reduction in sales of lenalidomide (a transient product). US contribution to total revenue remains high at 44.3%. (2 intensifying, 3 easing, 1 high-severity)
“US revenue in Q3FY26 increased by 1% QoQ accounting for 43.2% of consolidated revenue, base business remained stable despite lower transient product sales”
Concentration remains high. While US revenue dipped, Europe grew 18% YoY, meaning the combined reliance on these two regulated markets remains the primary driver of the business. (4 stable, 1 high-severity)
“USA 3,739 Europe 2,703 [Total Revenue] 8,646”
API revenue decline has worsened, falling 16.1% YoY and 14.4% QoQ. Management explicitly cites pricing pressures and geopolitical tensions as the cause. (5 intensifying)
“The Dayton facility... will begin contributing revenues significantly from FY27 onwards... We expect to ramp it [Pen-G] up to nearly 65 to 70% by March ‘26 against the last year average of 42%.”
See the full cited Risk analysis of Aurobindo Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.